{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-25-003838","form_type":"8-K","ticker":"SBFM","cik":"0001402328","company_name":"Sunshine Biopharma Inc.","filed_at":"2025-05-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.175650+00:00","generated_at":"2026-05-21T01:23:48.313322+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sunshine Biopharma Q1 revenue up 18% to $8.9M; net loss narrows","bullets":["Revenue of $8.9 million in Q1 2025, up 18% from $7.5M in Q1 2024.","Net loss improved to $1.18M from $1.28M in prior-year quarter.","Appointed Michel Roy as new Chief Commercial Officer.","Launched 6 new generic drugs: two antibiotics, two GI drugs, two schizophrenia drugs.","Completed preclinical studies confirming K1.1 mRNA-LNP activity against hepatocellular carcinoma."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-25-003838","json":"https://secwatch.observer/filing/0001683168-25-003838.json","markdown":"https://secwatch.observer/filing/0001683168-25-003838.md","text":"https://secwatch.observer/filing/0001683168-25-003838.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1402328/000168316825003838/0001683168-25-003838-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1402328/000168316825003838/sunshine_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T01:23:48.313322+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}